Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

Pharmaceutical Executive July 3, 2007 Sarah Houlton	Global Report: Five-Year Survivor: European Edition The UK government's attitude seems to be that oncology treatments are hugely expensive -- and that too much of the National Health Service budget is vanishing into the pockets of drug companies. Will cancer networks fill the gap?
Pharmaceutical Executive November 1, 2005 Sarah Houlton	Global Report: Drug Evaluation in the UK The availability of new medicines has been thrown into the limelight once more, with UK's National Institute for Health and Clinical Excellence being called upon to make dramatic improvements to the speed at which it carries out evaluations.
The Motley Fool August 29, 2011 Brian Orelli	Drug Approved for Few Patients -- but That's OK The age of personalized medicine is upon us. Earlier this month, the FDA approved Roche's melanoma drug Zelboraf for patients with a specific mutation in BRAF. And on Friday, the agency approved Pfizer's Xalkori for lung cancer patients that are ALK-positive.
BusinessWeek January 30, 2006 Catherine Arnst	Going Broke To Stay Alive Rising prices for cancer treatments are making patients - and doctors - balk.
The Motley Fool February 24, 2011 Brian Orelli	Profit From Personalized Medicine Pfizer's drug works well, but consider these companies instead.
The Motley Fool March 26, 2007 Rich Duprey	Acquisitions Mark Pharmaceutical Industry Japan's Eisai's newest acquisition continues the trend of pharmaceuticals buying up biotechs. Investors, take note.
Pharmaceutical Executive December 1, 2006 Sarah Houlton	Global Report: Not So NICE A new manifesto by the Association of the British Pharmaceutical Industry is designed to improve drug access in the UK, where industry has worried for years about poor uptake of new medicines.
The Motley Fool September 9, 2011 Frank Vinluan	GSK Halts Part of Breast Cancer Trial; Drug Can't Top Herceptin GlaxoSmithKline has halted part of a phase 3 breast cancer clinical study after an independent committee concluded that the GSK drug administered alone is unlikely to work better than a rival cancer drug from Roche.
BusinessWeek June 21, 2004 Catherine Arnst	Cancer Superdrugs, Costly Side Effects New therapies are extending lives, but the prices could weigh down the nation. Oncologists, pharmaceutical companies, and the government will have to focus on the best way to lower prices for these drugs.
BusinessWeek May 23, 2005 Catherine Arnst	If It Works for Breast Cancer... Studies are under way to see if promising strategies used against breast cancer can be used to fight other killers, such as lung, colon, and prostate cancer.
The Motley Fool May 8, 2009 Brian Orelli	Investing Against Breast Cancer Many companies are interested in both a cure and a large lucrative market. Which are the best investments now in this sector?
Pharmaceutical Executive October 1, 2008 Sarah Houlton	Open For Debate Tensions mount as stakeholders in the UK health industry attempt to work out drug cost problems.
The Motley Fool July 24, 2009 Brian Orelli	Juicing Up the Earnings Report How did Celgene turn an earnings release that met analysts' expectations while lowering revenue guidance on one of its drugs into an 18.6% increase in share price yesterday?
The Motley Fool March 23, 2009 Brian Orelli	Good News for Eli Lilly's Depression Drug Eli Lilly announces that the Food and Drug Administration has expanded the label of Symbyax to treat patients with treatment-resistant depression, meaning they haven't been helped by at least two other drugs.
The Motley Fool May 28, 2010 Brian Orelli	This Drug Doesn't Work. But All Is Not Lost. Novartis cancer drug fails one trial, but there's still hope.
BusinessWeek June 6, 2005 Catherine Arnst	Better Odds Against Breast Cancer New treatments for breast cancer are more effective, and easier to live with
The Motley Fool June 2, 2009 Brian Orelli	Pfizer: If You Can't Beat 'Em, Join 'Em Sutent fails. Again.
Scientific American August 2008 Jessica Wapner	Cancer Drug Costs May Help Doctors Select a Treatment In discussing treatments, cancer doctors plan to include cost.
BusinessWeek June 16, 2011 Langreth & Cortez	When Two Cancer Drugs Are Better Than One Drugmakers are collaborating to test combinations of genetically targeted cancer drugs in hopes of boosting survival rates.
BusinessWeek February 16, 2004 Catherine Arnst	Medicare vs. Cancer Patients Refusing to reimburse off-label treatment is far from the best way to cut costs.
The Motley Fool May 31, 2011 Brian Orelli	Profit From This Growing Drug Trend Cancer drugs press on.
The Motley Fool April 13, 2011 Brian Orelli	Abbott's Potential Billion-Dollar Problem Abbott's Humira forms antibodies in nearly a quarter of patients.
BusinessWeek August 26, 2010 Tom Randall	Cocktails Are Next For Cancer-Drug Makers Taking a cue from the cocktails of drugs that have made AIDS survivable, drugmakers are pursuing combination therapies against cancer.
The Motley Fool September 14, 2006 Brian Lawler	Close Failure for Genzyme Will Genzyme's Campath get approval? Investors shouldn't hold their breath.
The Motley Fool April 3, 2008 Brian Lawler	A Punch to Gilead's Competition A rival compound's bad data signals a better future for Gilead's lead drugs.
Managed Care March 2007 Lola Butcher	Plans Put Greater Emphasis On Cancer Management Increasingly, health plans are rolling out services designed to help cancer patients and, before that, plan members at a high risk of cancer, to improve their health care and, in doing so, limit costs.
The Motley Fool October 13, 2006 Rich Duprey	NICE Is Just Dumb The British health agency prohibits the use of certain Alzheimer's treatments because of cost.
The Motley Fool February 26, 2008 Brian Orelli	The Less-Flashy Prostate Cancer Treatment GTx shows off clinical trial data for a drug that counters the side effects of prostate cancer treatments.
The Motley Fool August 28, 2009 Brian Orelli	Abbott Signs Up Another One Abbott announces that it has set up a partnership with Pfizer to run tests on Pfizer's new drug.
Chemistry World May 5, 2015 Anthony King	Merger creates biggest supplier of unlicensed drugs Specialty pharma company Clinigen is to buy its rival Idis, making it the market leader in ethical unlicensed drug supply.
The Motley Fool December 1, 2005 Brian Gorman	Glaxo Follows the Biotechs The company's new focus on cancer drugs looks like a good move. Investors, take note.
The Motley Fool April 3, 2009 Brian Orelli	Pfizer + Sutent = One Exciting Roller Coaster This time on the down slope, unfortunately.
The Motley Fool March 31, 2009 Brian Orelli	A Good Start for a Potential Blockbuster Novartis' FDA approval for Afinitor is nice, but it needs another indication to be a blockbuster.
The Motley Fool September 14, 2009 Brian Orelli	More Tests for Drug for Cancer Patients The Vanilla trial might not have come up positive, but at least sanofi-aventis and Regeneron Pharmaceuticals will keep trying to show that aflibercept is capable of helping cancer patients live longer.
The Motley Fool May 30, 2006 Rich Duprey	NICE Not Playing Nice With Alzheimer's The British health authority proposes limiting availability of Alzheimer's treatments because of cost. What will this mean to drug-makers and their shareholders?
The Motley Fool August 22, 2006 Brian Gorman	NICE Unkind to Biotech Developments in the U.K.'s drug coverage may hurt U.S. biotechs. Biotech investors, keep your eyes on this issue.
Pharmaceutical Executive October 1, 2014 Leela Barham	The Gate Keeper Dr. David Haslam, Chair of the UK's National Institute of Health and Care Excellence, discusses what the quantitative calculations of value mean to patient access in today's messy world of real-time medicine.
The Motley Fool April 26, 2004 Alyce Lomax	Genentech's Lucky Day Genentech and OSI Pharmaceuticals jump in today's trading session after favorable trial results for a cancer drug.
The Motley Fool May 4, 2009 Robert Steyer	Beyond Provenge -- The Next Hot Cancer Drug? The search for prostate cancer treatments is filled with prospects and littered with failures. Which companies have the best chance of success?
Pharmaceutical Executive May 1, 2007 Patrick Clinton	The Topic of Cancer What will tomorrow's cancer commercialization model really look like? We asked four heavyweights from the world of oncology what they thought.
BusinessWeek June 6, 2005 Catherine Arnst	The Anti-Cancer Strategist Oncology specialist Judah Folkman pioneered a new treatment: Starve the tumor
The Motley Fool July 9, 2008 Brian Lawler	Predicting More Good News From Invitrogen Invitrogen gets a positive review from the FDA for one of its tests.
The Motley Fool September 17, 2007 Brian Orelli	Preventing Cancer, No Bones About It For Eli Lilly, the only thing better than having a drug with more than $1 billion in annual sales is getting it approved to treat more patients. That's what just happened with their cancer drug, EVISTA. Investors, take note.
The Motley Fool July 6, 2009 Brian Orelli	Lilly Shows Us How It's Done The company announces that the Food and Drug Administration had expanded the approval of its cancer drug, Alimta, to include maintenance therapy for nonsquamous, non-small cell lung cancer.
Chemistry World June 25, 2013 Emma Stoye	NHS to offer breast cancer prevention drugs New guidelines for the UK National Health Service suggest that women at high risk of breast cancer should be offered a five-year course of tamoxifen or raloxifene to prevent the disease developing.
The Motley Fool June 29, 2007 Rich Duprey	No More Mr. NICE Guy Pharmaceuticals take British advisory agency to court to approve Alzheimer's treatment.
BusinessWeek June 6, 2005	Inside Judah Folkman's Lab The pioneering cancer researcher, Dr. Judah Folkman, talks about the path that led to his discoveries and about how much remains to be done
The Motley Fool June 13, 2008 Brian Lawler	Glaxo Gears Up a Blockbuster One of the pharmaceutical's top new compounds scores final EU approval.
Managed Care June 2002	Oncologists: FDA needs to speed up approval of cancer-fighting drugs A Competitive Enterprise Institute survey of cancer specialists found that almost 8 of 10 oncologists think the FDA's approval process has "hurt their ability, at least once in their medical careers, to treat patients with the best possible care."
BusinessWeek May 9, 2005 Catherine Arnst	Genentech's Lessons For Big Pharma The biotech company focuses on science -- not marketing, acquisitions, or patents.